DK1869165T3 - Isolering af adulte multipotente celler ved vævsuspecifik alkalisk phosphatase - Google Patents

Isolering af adulte multipotente celler ved vævsuspecifik alkalisk phosphatase Download PDF

Info

Publication number
DK1869165T3
DK1869165T3 DK06721376.9T DK06721376T DK1869165T3 DK 1869165 T3 DK1869165 T3 DK 1869165T3 DK 06721376 T DK06721376 T DK 06721376T DK 1869165 T3 DK1869165 T3 DK 1869165T3
Authority
DK
Denmark
Prior art keywords
cells
stro
tnap
cell
antibody
Prior art date
Application number
DK06721376.9T
Other languages
English (en)
Inventor
Stan Gronthos
Andrew Christopher William Zannettino
Paul John Simmons
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Application granted granted Critical
Publication of DK1869165T3 publication Critical patent/DK1869165T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/56—Fibrin; Thrombin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)

Claims (7)

1. Fremgangsmåde til berigelse for adulte multipotente celler, hvilken fremgangsmåde omfatter (i) etablering af kontakt mellem en celleprøve og et an t i -TNAP-antistof under forhold, der tillader binding af an t i -TNAP-antistoffet til celler, der udtrykker TNAP, og separation af cellerne bundet til anti-TNAP-antistoffet; og (ii) dyrkning af cellepopulationen opnået i trin (i) for at berige for multipotente celler, der udtrykker STRO-1- markøren; og hvor ant i-TNAP-ant istof fet er et antistof, der binder til den samme epitop som STRO-3-ant istof fe t produceret af hybridomcel le I in jen deponeret hos ATCC den 19. december 2005 i henhold til bestemmelserne i Budapest t raktaten under deponer ingsadgangsnurrmer PTA-7282.
2. Fremgangsmåde ifølge krav 1, hvor ant i-TNAP-ant istof fet binder specifikt til BAP-i so formen af TNAP.
3. Fremgangsmåde ifølge krav 1, hvor ant i-TNAP-ant is tof fet er STRO-3-antistoffet produceret af hybridomcelI el injen deponeret hos ATCC den 19. december 2005 i henhold til bestemmelserne i Budapesttraktaten under deponeringsadgangsnummer PTA-7282.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvor ant i - TNAP-ant is tof fe t er bundet til en faststofpart ikel.
5. Fremgangsmåde til generering af en bestemt vævsspecifik cellepopulation, hvilken fremgangsmåde omfatter (i) etablering af kontakt mellem celleprøven og et an t i -TNAP-ant istof under forhold, der tillader binding af TNAP til anti-TNAP-anti stof fet, og separation af cellerne bundet til anti-TNAP-anti stof fet; (ii) dyrkning af cellepopulationen opnået i trin (i) for at berige for multipotente celler, der udtrykker STRO-1 - markø ren ; (iii) dyrkning af populationen af celler fra trin (ii) i nærvær af én eller flere stimulerende faktorer; og udsættelse af den dyrkede population for forhold, der begunstiger differentiering af de adulte multipotente celler til en specifik vævstype.
6. STRO-3 hybridomcel le I inje deponeret hos ATCC den 19. december 2005 i henhold til bestemmelserne i Budapesttraktaten under deponeringsadgangsnummer PTA-7282.
7. STRO-3-anti s tof produceret af hybri domcel le I injen deponeret hos ATCC den 19. december 2005 i henhold til bestemmelserne i Budapesttraktaten under deponeringsadgangsnummer PTA-7282.
DK06721376.9T 2005-04-12 2006-04-12 Isolering af adulte multipotente celler ved vævsuspecifik alkalisk phosphatase DK1869165T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67025005P 2005-04-12 2005-04-12
PCT/AU2006/000494 WO2006108229A1 (en) 2005-04-12 2006-04-12 Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase

Publications (1)

Publication Number Publication Date
DK1869165T3 true DK1869165T3 (da) 2016-02-01

Family

ID=37086526

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06721376.9T DK1869165T3 (da) 2005-04-12 2006-04-12 Isolering af adulte multipotente celler ved vævsuspecifik alkalisk phosphatase

Country Status (11)

Country Link
US (6) US8367405B2 (da)
EP (3) EP1869165B1 (da)
JP (2) JP5462483B2 (da)
KR (3) KR101446634B1 (da)
CN (1) CN101248171B (da)
AU (2) AU2006235211B2 (da)
CA (1) CA2604493C (da)
DK (1) DK1869165T3 (da)
ES (1) ES2654428T3 (da)
HK (1) HK1123071A1 (da)
WO (1) WO2006108229A1 (da)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
CA2578113A1 (en) * 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
JP5202953B2 (ja) * 2004-11-08 2013-06-05 ザ ジョンズ ホプキンス ユニバーシティー 心臓幹細胞
EP1869165B1 (en) * 2005-04-12 2015-10-21 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
CN101395266B (zh) 2005-12-29 2018-06-15 人类起源公司 胎盘干细胞群
EP2046349B1 (en) * 2006-07-12 2015-09-09 Mesoblast, Inc. Treatment of excessive neovascularization
WO2008058273A2 (en) * 2006-11-09 2008-05-15 The Johns Hopkins University Dedifferentiation of adult mammalian cardiomyocytes into cardiac stem cells
ES2923016T3 (es) * 2007-08-06 2022-09-22 Mesoblast Inc Células precursoras mesenquimales TNAP+ para el tratamiento de enfermedades del tejido conectivo
RU2010116271A (ru) * 2007-09-26 2011-11-10 Селджин Селльюлар Терапьютикс (Us) Ангиогенные клетки из плацентарного перфузата человека
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
US20100010549A1 (en) * 2008-03-05 2010-01-14 Neville Alleyne device and method of minimally invasive extracapsular ligamentous augmentation for canine stifle ligament injuries
CN105030828B (zh) 2008-06-25 2020-10-02 麦瑟布莱斯特公司 椎间盘的修复和/或重建
DE102008032236A1 (de) 2008-06-30 2010-04-01 Eberhard-Karls-Universität Tübingen Isolierung und/oder Identifizierung von Stammzellen mit adipozytärem, chondrozytärem und pankreatischem Differenzierungspotential
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
KR20210010648A (ko) 2008-08-20 2021-01-27 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
EP2331109B1 (en) 2008-08-22 2013-05-29 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2367932B1 (en) 2008-11-19 2019-06-12 Celularity, Inc. Amnion derived adherent cells
EP2350266B1 (en) * 2008-11-20 2015-07-29 Mesoblast, Inc. Method for treating or preventing a pancreatic dysfunction
US8309343B2 (en) 2008-12-01 2012-11-13 Baxter International Inc. Apparatus and method for processing biological material
WO2011031299A1 (en) * 2009-08-28 2011-03-17 Mount Sinai School Of Medicine Of New York University Intrapericardial injections
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
CA2803641A1 (en) 2010-07-02 2012-01-05 Mesoblast, Inc. Treatment of t-cell mediated immune disorders
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
EP2709634B1 (en) * 2011-05-19 2020-09-09 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
CA2837895C (en) * 2011-06-03 2021-07-27 Mesoblast, Inc. Methods of treating or preventing neurological diseases
CN103826646A (zh) 2011-06-03 2014-05-28 麦瑟布莱斯特公司 治疗中风的影响的方法
EP3653218A1 (en) 2011-07-04 2020-05-20 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
CA2840307C (en) 2011-07-06 2021-10-19 Cell Therapy Limited Progenitor cells of mesodermal lineage
TR201809635T4 (tr) 2011-09-09 2018-07-23 Mesoblast Inc Osteoblastik fonksiyonun arttırılmasına yönelik yöntemler.
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
CA2881394C (en) 2012-08-13 2024-05-14 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US10028979B2 (en) * 2012-12-12 2018-07-24 Mesoblast, Inc. Methods of treating or preventing respiratory conditions
SG10201705061RA (en) 2012-12-12 2017-07-28 Mesoblast Inc Treatment of Diseases of Endothelial Dysfunction and Inflammation
AU2014209218B2 (en) * 2013-01-25 2018-06-07 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
EP3019598A1 (en) * 2013-07-11 2016-05-18 INSERM - Institut National de la Santé et de la Recherche Médicale Method for obtaining a population of isolated brite adipocytes
EP3027235A1 (en) 2013-07-30 2016-06-08 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
EP3030194B1 (en) * 2013-08-09 2019-03-13 Merit Medical Systems, Inc. Vascular filter delivery systems
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
US9901478B2 (en) 2014-03-11 2018-02-27 Chine, Llc Methods and apparatuses for the external distraction in the assistance of spinal deformities
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
JP6882161B2 (ja) 2014-04-07 2021-06-02 メゾブラスト・インターナショナル・エスアーエールエル 改善された幹細胞組成物
EP4137146A1 (en) 2014-06-10 2023-02-22 Mesoblast International Sàrl Treatment of immune disorders
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
ES2779410T3 (es) 2014-11-07 2020-08-17 Arkema France Sistemas y métodos de recubrimiento extraíbles
JP2018505726A (ja) 2015-01-16 2018-03-01 スピネオベイションズ・インコーポレーテッド 脊椎円板を処置する方法
US11795435B2 (en) 2015-05-05 2023-10-24 Mesoblast International Sárl; Potency assay
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
EP3619294A1 (en) 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
CN107475098B (zh) * 2017-08-15 2023-08-15 中国人民解放军第二军医大学第二附属医院 一种无菌条件下髌下脂肪垫快速匀浆分装装置及方法
TWI656215B (zh) * 2017-11-28 2019-04-11 宏齊科技股份有限公司 自周邊血液製備間質幹細胞群的方法及其用途
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
SG11202103901YA (en) 2018-10-31 2021-05-28 Mesoblast Int Sarl Expansion of hematopoietic stem cells
CN113631173A (zh) 2019-01-02 2021-11-09 迈索布拉斯特国际有限公司 治疗腰痛的方法
KR20210110822A (ko) 2019-01-03 2021-09-09 메조블라스트 인터내셔널 에스에이알엘 시력 향상을 위한 방법
WO2020157660A1 (en) 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
GB2604400A (en) 2021-03-05 2022-09-07 Qv Bioelectronics Ltd Biphasic injectable electrode
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖
CN114085911B (zh) * 2022-01-19 2022-05-17 珠海圣美生物诊断技术有限公司 一种检测肿瘤细胞或肿瘤细胞碎片的方法
WO2024030976A2 (en) * 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
CN115554467B (zh) * 2022-11-10 2024-01-30 奥精医疗科技股份有限公司 一种颅骨修复材料及其制备方法
WO2024121819A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Method of treating inflammation with cellular compositions
WO2024121820A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Pre-licensed composition and cell culture methods
WO2024121821A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Conditioned media and use of the same
WO2024121818A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3089815A (en) * 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5693531A (en) 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
JP3591837B2 (ja) 1994-02-17 2004-11-24 ニューヨーク・ブラッド・センター・インコーポレイテッド フィブリン膠およびリポソームを含有する生物学的生体接着剤組成物、その製造方法および使用
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2207289C (en) 1994-12-07 2005-04-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
CA2238434A1 (en) 1995-12-15 1997-06-19 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US6200606B1 (en) 1996-01-16 2001-03-13 Depuy Orthopaedics, Inc. Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration
US5824084A (en) 1996-07-03 1998-10-20 The Cleveland Clinic Foundation Method of preparing a composite bone graft
EP1171006B1 (en) 1999-04-16 2006-03-29 Wm. MARSH RICE UNIVERSITY Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol)
US6355699B1 (en) * 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US6468527B2 (en) * 2000-06-22 2002-10-22 Sam L. Austin Biological bioadhesive composition and methods of preparation and use
US20030027151A1 (en) * 2000-08-18 2003-02-06 Warman Matthew L. Regulator gene and system useful for the diagnosis and therapy of osteoporosis
IL159578A0 (en) * 2001-07-06 2004-06-01 Geron Corp Messenchymal cells and osteoblasts from human embryonic stem cell
JP2003052365A (ja) 2001-08-20 2003-02-25 Japan Science & Technology Corp 哺乳動物からの間葉系幹細胞の分離及びその利用方法
DE10242338A1 (de) * 2002-09-09 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Isolierung und/oder Identifizierung mesenchymaler Stammzellen und Verfahren zur Isolierung und/oder Identifizierung mesenchymaler Stammzellen
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
EP1869165B1 (en) * 2005-04-12 2015-10-21 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
CA2908068A1 (en) 2013-03-28 2014-10-02 Level 3 Communications, Llc System and method for network provisioning

Also Published As

Publication number Publication date
JP2014076055A (ja) 2014-05-01
HK1123071A1 (en) 2009-06-05
US20160264683A1 (en) 2016-09-15
EP1869165A4 (en) 2008-12-31
KR101617319B1 (ko) 2016-05-02
AU2010257342A1 (en) 2011-01-20
CA2604493A1 (en) 2006-10-19
JP5972851B2 (ja) 2016-08-17
CN101248171A (zh) 2008-08-20
EP1869165B1 (en) 2015-10-21
EP3327116A1 (en) 2018-05-30
ES2654428T3 (es) 2018-02-13
AU2006235211A1 (en) 2006-10-19
KR20160052779A (ko) 2016-05-12
EP1869165A1 (en) 2007-12-26
WO2006108229A1 (en) 2006-10-19
US20180009905A1 (en) 2018-01-11
US9783617B2 (en) 2017-10-10
US20090074728A1 (en) 2009-03-19
CN101248171B (zh) 2015-11-25
US20200332023A1 (en) 2020-10-22
EP2399991B1 (en) 2017-09-27
JP5462483B2 (ja) 2014-04-02
US20150267171A1 (en) 2015-09-24
KR20070120598A (ko) 2007-12-24
US20130209417A1 (en) 2013-08-15
KR20140094640A (ko) 2014-07-30
KR101446634B1 (ko) 2014-10-16
KR101682046B1 (ko) 2016-12-02
JP2008538495A (ja) 2008-10-30
CA2604493C (en) 2015-12-22
EP2399991A1 (en) 2011-12-28
AU2006235211B2 (en) 2010-10-14
US8367405B2 (en) 2013-02-05

Similar Documents

Publication Publication Date Title
US20200332023A1 (en) Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
JP5927080B2 (ja) 分化多能性増殖間葉系前駆細胞子孫（ｍｅｍｐ）およびその使用
KR101598947B1 (ko) 간엽 전구세포의 증식 및/또는 생존성 증강 방법
AU2013202303A1 (en) Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
AU2020201937B2 (en) Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase